Candel Therapeutics (NASDAQ:CADL – Get Free Report) and Immix Biopharma (NASDAQ:IMMX – Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, risk, valuation, earnings, analyst recommendations, profitability and dividends.
Profitability
This table compares Candel Therapeutics and Immix Biopharma’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Candel Therapeutics | N/A | -41.00% | -26.81% |
| Immix Biopharma | N/A | -205.35% | -110.63% |
Risk and Volatility
Candel Therapeutics has a beta of -0.94, suggesting that its share price is 194% less volatile than the S&P 500. Comparatively, Immix Biopharma has a beta of 0.23, suggesting that its share price is 77% less volatile than the S&P 500.
Analyst Ratings
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Candel Therapeutics | 1 | 1 | 3 | 1 | 2.67 |
| Immix Biopharma | 1 | 1 | 1 | 0 | 2.00 |
Candel Therapeutics currently has a consensus price target of $20.00, indicating a potential upside of 259.71%. Immix Biopharma has a consensus price target of $8.00, indicating a potential upside of 288.35%. Given Immix Biopharma’s higher probable upside, analysts clearly believe Immix Biopharma is more favorable than Candel Therapeutics.
Earnings & Valuation
This table compares Candel Therapeutics and Immix Biopharma”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Candel Therapeutics | $120,000.00 | 2,543.70 | -$55.18 million | ($0.69) | -8.06 |
| Immix Biopharma | N/A | N/A | -$21.61 million | ($0.77) | -2.68 |
Immix Biopharma has lower revenue, but higher earnings than Candel Therapeutics. Candel Therapeutics is trading at a lower price-to-earnings ratio than Immix Biopharma, indicating that it is currently the more affordable of the two stocks.
Institutional & Insider Ownership
13.9% of Candel Therapeutics shares are owned by institutional investors. Comparatively, 11.3% of Immix Biopharma shares are owned by institutional investors. 16.6% of Candel Therapeutics shares are owned by company insiders. Comparatively, 55.4% of Immix Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Summary
Candel Therapeutics beats Immix Biopharma on 8 of the 13 factors compared between the two stocks.
About Candel Therapeutics
Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. The company also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent high-grade glioma. It also develops the?enLIGHTEN Discovery Platform, a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts.
About Immix Biopharma
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. The company was incorporated in 2012 and is headquartered in Los Angeles, California.
Receive News & Ratings for Candel Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Candel Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
